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Abstract
Background: Recent understanding on cancer therapy indicated that targeting metastatic signature or angiogenic switch
could be a promising and rational approach to combat cancer. Advancement in cancer research has demonstrated the
potential role of various tumor suppressor proteins in inhibition of cancer progression. Current studies have shown that
axonal sprouting inhibitor, semaphorin 3A (Sema 3A) acts as a potent suppressor of tumor angiogenesis in various cancer
models. However, the function of Sema 3A in regulation of melanoma progression is not well studied, and yet to be the
subject of intense investigation.
Methodology/Principal Findings: In this study, using multiple in vitro and in vivo approaches we have demonstrated that
Sema 3A acts as a potent tumor suppressor in vitro and in vivo mice (C57BL/6) models. Mouse melanoma (B16F10) cells
overexpressed with Sema 3A resulted in significant inhibition of cell motility, invasiveness and proliferation as well as
suppression of in vivo tumor growth, angiogenesis and metastasis in mice models. Moreover, we have observed that Sema
3A overexpressed melanoma clone showed increased sensitivity towards curcumin and Dacarbazine, anti-cancer agents.
Conclusions: Our results demonstrate, at least in part, the functional approach underlying Sema 3A mediated inhibition of
tumorigenesis and angiogenesis and a clear understanding of such a process may facilitate the development of novel
therapeutic strategy for the treatment of cancer.
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Introduction
Melanoma or malignancies of melanocytic tissues have been
identified as one of the most malignant cancer in the United States
and around the world. In the year 2010, more than 68,130 new
cases of melanoma have been reported in the United States with a
result of 8,700 deaths [1]. Malignant progression of cancer cells
depends on intrinsic crosstalk between several factors, overexpres-
sion of various oncogenic molecules and loss of function of tumor
suppressor genes. Therefore, understanding the mechanisms of
various tumor suppressor genes in regulation of cancer progression
and their possible role in cancer therapeutics is under intense
investigation. Semaphorins have been originally known as a large
family of evolutionary conserved axonal guidance molecules [2,3].
The role of semaphorins in various physiological as well as
pathophysiological processes including cell migration, regulation
of immune response, angiogenesis and cancer have recently been
studied [4]. Among various semaphorins, selected members of
semaphorin 3 (Sema 3) family are involved in suppression of tumor
progression and have been considered as potent tumor suppressors
[5]. Loss of expressions of Sema 3B and Sema 3F gene (deletion of
chromosome 3p21.3 in human) have been shown to associate with
lung cancer progression [6–8]. On the other hand, overexpression
of these molecules inhibits tumor cell proliferation and in vivo
tumor growth [9–12]. Moreover, Semaphorin 3A (Sema 3A),
another member of this family is shown to inhibit angiogenesis and
acts as tumor suppressor [13–16].
Sema 3A is originally described as a secretory protein with
potent axonal repulsive activity [17,18]. Polleux et al have
identified the chemoattractive effect of Sema 3A on cortical apical
dendrites [19] and shown that Sema 3A acts as a crucial regulatory
molecule for neuronal development. However, Serini et al have
observed a significant vascular defect in Sema 3A null mice [16].
In this study, we have deciphered the function of Sema 3A beyond
brain, and demonstrated that this protein could play an important
role in melanoma growth. Knockdown of endogenous Sema 3A
significantly induce in vitro migration of human breast cancer cell
and indicated that Sema 3A may act as a potent tumor suppressor
[20]. Overexpression of Sema 3A attenuates invasion and matrigel
adhesion of human prostate cancer cells [21]. Moreover, loss of
Sema 3A inhibitory loop in hormone-refractory human prostatic
cancer has been recently identified by tissue microarray analysis
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be an important therapeutic target for prostate cancer progression
[22]. Furthermore, overexpression of Sema 3A significantly
suppresses in vivo breast tumor growth in mouse xenograft model
[23]. However, the function of Sema 3A in regulation of
melanoma progression is not well studied, and yet to be a field
of intense investigation.
Angiogenesis, or formation of new blood vessel from the existing
one has been considered as the most important step during tumor
progression [24]. Current advancement in cancer research has
shown that targeting angiogenic pathways could be a more rational
and promising anti-cancer therapeutic approach [25]. To date,
vascular endothelial growth factor (VEGF) is considered as one of
the most potent angiogenic factor that governs tumor angiogenesis
[26]. Interaction between VEGF and one of its co-receptor
neuropilin 1 (NRP1) is known to play an important role in tumor
angiogenesis [27,28] and therefore blocking their interaction could
be a rational anti-angiogenic therapeutic approach for cancer
treatment [28,29]. Moreover, NRP1 has been identified as one of
the co-receptors of Sema 3A [30,31]. Miao et al. have shown that
Sema 3A and/or VEGF act as competitive ligand for binding to
NRP1 and described that Sema 3A can attenuate VEGF-induced
endothelial cell motility [32]. Thus, Sema 3A could act as a potent
inhibitor of tumor angiogenesis by disrupting the interaction
between VEGF and NRP1. Very recently, using transgenic mice
model, Maione et al. have shown that Sema 3A acts as an
endogenous angiogenesis inhibitor that blocks tumor growth by
normalizing tumor vasculature [33]. Earlier data have shown that
Sema 3F, another member of Sema 3 family, attenuates melanoma
progression by inhibiting angiogenesis [34]. However, the correla-
tion between Sema 3A expression and melanoma progression as
well as angiogenesis is not clearly understood. Therefore, using
multiple models, we have demonstrated the novel function of Sema
3A in suppression of melanoma progression and angiogenesis. Our
study might be useful to develop more rational Sema 3A-mediated
therapeutic strategy for the next generation of cancer management.
Materials and Methods
Cell lines, reagents and antibodies
The murine melanoma cell lines (B16F1 and B16F10) and
human melanoma cell lines (A375 and SK-Mel-28) were purchased
from American Type Culture Collection (ATCC, Manassas, VA),
cultured in DMEM supplemented with 10% fetal bovine serum,
100 units/ml penicillin, 100 mg/ml streptomycin and 2 mM
glutamine in a humidified atmosphere of 5% CO2 and 95% air
at 37uC. Human umbilical vein endothelial cells (HUVEC) were
cultured in EBM according to the manufacturer’s instructions
(Lonza, Walkersville, MD). Human recombinant Sema 3A (Cat
no. AF1250-S3-025) and mouse recombinant Sema 3A (Cat
no. 5926-S3-025) were purchased from R&D Systems. Goat anti-
Sema 3A (Cat no. SC 1148), rabbit anti-a-tubulin (SC-135659),
rabbit anti-PARP (SC-25780) antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-vWF
antibody (Cat no. HPA002082), PI, DAPI, FITC-conjugated
phalloidin, fibronectin, Dacarbazine (DTIC), curcumin were
purchased from Sigma (St. Louis, MO). Boyden type cell migration
chambers were obtained from Corning (Corning, NY). Growth
factor depleted matrigel and matrigel coated invasion chambers
were obtained from BD Bioscience (Bedford, MA). Mouse anti-
Sema 3A (Cat no. MAB-1250) and anti-neuropilin1 (Cat
no. AF566) antibodies were purchased from R&D System (Minne-
apolis, MN). Rabbit anti-phospho p53 (Ser-15) (Cat no. 9284)
antibody was obtained from Cell Signaling Technologies (Danvers,
MA). The C57BL/6miceweremaintained atExperimentalAnimal
Facility (EAF) of National Center for Cell Science (NCCS), Pune,
India. The study was approved by Institutional Animal Care and
Use Committee (IACUC), NCCS (Project Approval No. NCCS/
EAF/2007/B116). Sema 3A siRNA was purchased from Dharma-
con International (Lafayette, CO). Human Sema 3A and GAPDH
specific TaqMan gene expression quantitative real time PCR (Q-
PCR) assay related reagents were procured from Applied
Biosystems (Carlsbad, CA). BrdU labeling and detection kit was
purchased from Roche. Anti-Goat Cy2 and anti-rabbit Cy3 were
purchased from Chemicon International.
RNA isolation, semi-quantitive RT–PCR and Q-PCR
RNA isolation and reverse transcription-polymerase chain
reaction (PCR) were performed as described earlier [35]. Total
RNA was isolated from B16F1, B16F10, A375 and SK-Mel-28
cells by using Trizol reagent (Invitrogen) and reverse transcription-
PCR was performed using following sets of primers: Sema 3A
forward: 59-CAG CCA TGT ACA ACC CAG TG-39; Sema 3A
reverse: 59-ACG GTT CCA ACA TCT GTT CC-39; GAPDH
forward: 59-ACT CCA CTC ACG GCA AAT TC-39; GAPDH
reverse: 59-CCT TCC ACA ATG CCA AAG TT-39. Q-PCR was
performed with TaqMan gene expression assay (Applied Biosys-
tems) according to manufacture’s instruction. GAPDH was used as
internal control. The PCR products were analyzed by electro-
phoresis using 1.0% agarose gel.
Generation of Sema 3A stable clones
Human Sema 3A cDNA in PCEP4 expression vector (H-Sema
3A-AP; a generous gift from Prof. Alex Kolodkin, Johns Hopkins
University School of Medicine, Baltimore, Maryland, USA) was
transfected in B16F10 cells using lipofectamine 2000 (Invitrogen;
Carlsbad, CA). After transfection, cells were selected with 400 mg/
ml hygromycin and three positive clones were isolated and
denoted as clone 1, 2 and 3.
Melanoma clinical specimen analysis
Normal skin biopsy and malignant melanoma specimens were
collected from local hospitals with informed consent. Tissue
sections were stained with hematoxylin and eosine and the
occurrence of melanoma in these samples was analyzed with the
help of expert onco-pathologist. The expression profiles of Sema
3A and phospho p53 (Ser-15) were analyzed by immunofluores-
cence in tissue sections using their specific antibodies and
visualized under confocal microscopy (Zeiss) as described earlier
[35,36].
Western Blot Analysis
The expression of Sema 3A in control or Sema 3A clones was
determined by Western blot using anti-Sema 3A antibody as
described [28]. The effect of Sema 3A on curcumin-induced
PARP cleavage was also determined using anti-PARP antibody.
Matrigel colony formation assay
Matrigel colony formation assay was performed on growth
factor depleted matrigel coated plate. Briefly, 250 ml cold matrigel
was coated on 24 well plates and the plates were kept at 37uC for
1 h for polymerization. Equal number of cells (control B16F10 or
clone 2) were grown on matrigel coated plates and incubated at
37uC for 7 days. After termination of experiments, colonies were
visualized under microscope (Nikon) and photographed.
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Cells(controlandclone 2)weregrownonfibronectincoatedcover
slips for 6 h. After 6 h, cells were fixed with 2% paraformaldehyde
and stained with FITC-conjugated phalloidin and visualized and
photographed under fluorescence microscope (Zeiss).
In separate experiments, B16F10, clone2 and SK-Mel-28 cells
were plated on cover slips and incubated in serum free media for
24 h. SK-Mel-28 cells were either treated with Sema-3A recombi-
nant protein (100 ng/ml) or vehicle for 24 h. Cells were fixed with
2% paraformaldehyde, stained with anti-Ser15-phospho-p53 anti-
body and visualized under confocal microscope (Zeiss). Nuclei were
stained with PI. To analyze the effect of curcumin on nuclear
morphology, equal number of cells (control B16F10 and clone 2)
were plated on cover slips and treated with indicated concentrations
of curcumin. Cells were fixed and stained with propidium iodide as
described earlier and visualized under fluorescence microscope [37].
Co-migration and co-invasion assays
Invasion assay was performed in matrigel coated invasion
chambers (BD Bioscience) using control B16F10 and clone 2 cells
as described [38]. Briefly, B16F1, B16F10 or clone 2 were added to
theupperportionoftheBoydenchamberand incubatedat37uCfor
18 h. In separate experiments, conditioned media collected either
from clone 2 (Sema 3A overexpressed) or Sema 3A siRNA
transfected B16F1 or B16F1 (with or without Sema 3A antibody)
were used in the lower chamber as chemoattractant for B16F10
migration. In another experiments, A375 and SK-Mel-28 cells,
treated with 100 ng/ml of Sema 3A were used in the upper portion
of invasion chambers. FBS was used as chemoattractant. The cells
invaded to the reverse side of the filter were stained, photographed,
counted in 3 high-power fields (C/HPF) under an inverted
microscope (Nikon), analyzed statistically and represented in the
form of bar graph.
The endothelial-melanoma cell interaction was shown by direct
co-migration or co-invasion assays as described [28]. Briefly,
HUVEC were added in upper chamber and control B16F10 or
clones 2 cells were used in lower chamber. Anti-NRP1 blocking
antibody was used in upper chamber. In separate experiments,
conditioned media collected either from clone 2 (Sema 3A
overexpressed) or Sema 3A siRNA transfected B16F1 or B16F1
(with or without Sema 3A Ab) were used in the lower chamber.
FBS serve as chemoattractant for HUVEC migration and
invasion. After 18 h, the migrated or invaded HUVEC in the
reverse side of the filter were stained, photographed, analyzed
statistically and represented graphically.
BrdU incorporation assay
SK-Mel-28 cells were seeded on coverslip and treated with
100 ng/ml Sema 3A for 24 h followed by incubation with
complete media supplemented with BrdU for another 24 h. Cells
were fixed with 100% cold methanol and stained with BrdU
labeling and detection kit (Roche), visualized under fluorescence
microscope, photographed and analyzed.
Wound assay and time laps microscopy
To further confirm the motility of control B16F10 and clone 2
cells, wound assay was performed as described [28,36]. Briefly,
clone 2 cells either alone or treated with anti-Sema 3A or anti-
NRP1 blocking antibody were used for wound assay. In separate
experiments, control B16F10 cells either alone or treated with
conditioned media obtained from clone 2 were used. After 18 h,
wound photographs were taken under inverted microscope (Nikon).
The wound migration was also visualized under time laps
microscopy. Confluent monolayer of cells was wounded and the
migration of the cells towards the wound was monitored and
photographed under Nikon time laps microscope in an interval of
10 min up to 18 h and represented in the form of videousing Image
Pro-Plus software after compiling the images into a movie. To
further validate the effect of endogenous Sema 3A on melanoma
migration, B16F1 cells were either silenced using Sema 3A specific
siRNA or pretreated with Sema 3A blocking antibody and analyzed
for wound assay. Migration assay was also performed using A375
and SK-Mel-28 cells treated with Sema 3A (100 ng/ml) for 18 h.
MTT assay
The effect of Sema 3A on melanoma cell proliferation was
determined by MTT (3-{4,5-dimethylthiazol-2-yl}-2,5-diphenyl
tetrazolium bromide) assay. Briefly, control B16F10 or clone 2
cells were plated and allowed to grow at 37uC. Both cells were
treated with Dacarbazine (0–400 mM) and curcumin ((0–50 mM)
and MTT was added to the cells and incubated at 37uC for 4 h.
The isopropanol was added to the cells, absorbance was measured
in an ELISA reader (Bio-Rad) at 570 nM.
DNA ladder assay
Both control B16F10 and clone 2 cells either untreated or
treated with two different concentrations of curcumin were
incubated at 37uC for 12 h, lysed in ladder assay buffer (10 mM
Tris-HCl, pH 8.0 containing 1 mM EDTA, 0.1% SDS and
50 mg/ml Proteinase K) and genomic DNA was isolated by
isopropanol precipitation method. Equal amount of DNA was
analyzed by 2% agarose gel electrophoresis.
In vivo tumorigenicity, in vivo invasion, histopathology
and immunohistochemistry
Control B16F10 and clone 2 cells (1610
6) were injected
subcutaneously into the dorsal flank region of C57BL/6 male
mice (6–8 weeks old). In separate experiments, serum free
conditioned media collected from clone 2 cells was injected twice
a week into the tumor site of mice generated by control cells.
Tumor length and width were measured every week. After 4
weeks, mice were sacrificed, photographed, tumors were dissected
out, weighted and used for histopathological and immunohisto-
chemical studies. The mice were also dissected ventrally,
photographed and the metastasized organs such as liver, intestine
and kidney were used for histopathological studies.
In vivo metastasis study by intra-cardiac injection
Control B16F10 and clone 2 cells (1610
5) were injected
intracardiacly into anesthetized C57BL/6 male mice (6–8 weeks
old). After 3 weeks, mice were sacrificed; photographed, metasta-
sized organs (lung, liver and intestine) were dissected out and used
for histopathological studies.
Statistical analysis
The cell migration, invasion, MTT assays, tumor-endothelial
interaction assays, tumor weights and volumes were analyzed
statistically. Statistical differences were determined by paired Student’s
t test. Differences were considered significant when P,0.05.
Results
Expression profile of Sema 3A in human melanoma
clinical specimens and its correlation with melanoma
growth
Clinicopathological studies on human melanoma specimens have
shown that melanoma progression is associated with angiogenesis
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samples and 5 normal skin biopsy samples by histopathology and
immunohistochemistry. The clinical samples were collected from
local hospital with informed consent. The occurrences of melanoma
in these samples were examined by H&E staining and the
micrographs were taken in 106magnification (Fig. 1A, panel a–e
and 1B panel a–h).The expressionlevel of Sema3Ainthese samples
was determined by immunohistochemistry using anti-Sema 3A
antibody.Theresultsrevealedthatsignificant expressionofSema3A
was observed in normal skin biopsy specimens (Fig. 1A, panel f–j).
However, the level of Sema 3A was significantly reduced in all 8
melanoma tissue sections indicating that loss of Sema 3A level
may be linked with melanoma growth (Fig. 1B, panel i–p).
Taken together,thesedata suggestedthatlossof Sema3A expression
is associated with melanoma progression in human clinical
specimens.
Generation of Sema 3A clone in murine melanoma cells
To examine the endogenous level of Sema 3A, we have used
two different murine melanoma cell lines. Our RT-PCR and
Western blot analysis data revealed that low metastatic melanoma
cells (B16F1) express significantly higher level of Sema 3A as
compared to highly metastatic (B16F10) cells (Fig. 1C and data not
shown). To further study the level of Sema 3A in human
melanoma cells (A375 and SK-Mel-28), Q-PCR was performed.
The data showed that A375 cells have significantly higher Sema
3A expression than SK-Mel-28 cells (Fig. S1A).
To investigate the role of Sema 3A on melanoma progression, we
generated Sema 3A positive stable clone in highly metastatic
B16F10 cells as described under material and methods. Our results
revealed that among three hygromycin resistance Sema 3A clones,
clone 2 expressed high level of Sema 3A as compared to clones 1
and 3 (Fig. 1D). Hence clone 2 is used for all further studies.
Figure 1. Histopathological and immunohistochemical analyses of human normal skin biopsy and malignant melanoma tissues.
(A&B) Five normal skin biopsy and eight malignant melanoma specimens were stained with hematoxylin and eosine and the histopathologic
micrographs were visualized at 106 magnifications (Fig. 1A, panels a–e, & Fig. 1B, panels a–h). Tissue sections were also analyzed
immunohistochemially for visualizing the expression of Sema 3A (Fig. 1A, panels f–j & Fig. 1B, panels i–p). Sema 3A was stained with Cy2
(Green). Note that significant loss of Sema 3A expression was detected in malignant melanoma tissue samples as compared to normal skin samples.
(C) Endogenous expression of Sema 3A mRNA in B16F1 and B16F10 cells as detected by RT-PCR. GAPDH was used as loading control. (D) Expression
of Sema 3A in B16F10 clones were analyzed by Western blot using specific antibody. The second clone (lane 3, denoted as clone 2) shows
significantly higher expression of Sema 3A as compared to other clones and control B16F10 cells. The data represent three independent experiments
exhibiting similar results.
doi:10.1371/journal.pone.0033633.g001
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phenotype of B16F10 cells
Earlier studies have shown that invasive behavior of melanoma
cells is one of the key phenomena during melanoma progression
[40]. Colony formation on matrigel has been frequently employed
as a reliable assay to determine the in vitro tumorigenicity and
metastatic phenotype of cancer cells [41,42]. To study the effect of
Sema 3A on in vitro tumorigenicity of melanoma cells, matrigel
colony formation assay was performed. The results revealed that
clone 2 cells exhibits significantly reduced colony formation on
matrigel as compared to control B16F10 cells (Fig. 2A, panel a).
To investigate the role of Sema 3A on stress fibre formation, both
the control B16F10 and clone 2 cells were grown in fibronectin
coated plates and stained with FITC-conjugated phalloidin. The
results showed that there was significant increase in actin stress
fiber (indicated by arrow) and lamellipodia formation in control
cells as compared to clone 2 (Fig. 2A, panel b). These data
suggested that overexpression of Sema 3A attenuates in vitro
metastatic phenotype of melanoma cells.
Effect of exogenous Sema 3A on melanoma cell
migration and invasion
To determine the effect of exogenous Sema 3A on human
melanoma cell migration and invasion, we have used two different
human malignant melanoma cell lines, A375 and SK-Mel-28.
Both these cells exhibited reduced migration when treated with
recombinant Sema 3A (Fig. 2D). We have also observed that
untreated SK-Mel-28 cells exhibit significantly higher invasion as
Figure 2. Loss-and-gain of Sema 3A functions and it’s correlation with metastatic phenotype of melanoma cells. (A) panel a, equal
number of control B16F10 and clone 2 cells (1610
4) were grown on matrigel coated plate and incubated at 37uC for 7 days. Colony photographs
were taken at 106magnification. Panel b, control B16F10 and clone 2 cells (1610
4) were plated on fibronectin coated coverslips and incubated for
6 h. Cells were fixed in 2% PFA and stained with FITC-conjugated phalloidin (green). Stress fibers were shown by arrows. Nuclei were stained with PI
(red). Photographs were taken at 606magnification. (B) The effect of Sema 3A on B16F10 cell motility was performed by wound migration assay.
Control B16F10 or clone 2 positive cells were used for wound migration. In separate experiments, clone 2 positive cells either treated with anti-Sema
3A or anti-NPR1 blocking antibody were used for wound migration assay. In another experiments, control B16F10 cells were incubated with
conditioned medium (CM) collected from clone 2 and wound migration assay was performed. After 18 h, cells were visualized and photographed
under Nikon microscope at 106magnification. (C) To further study the loss-of-function of Sema 3A in regulating melanoma cell migration, wound
assay was performed using B16F1 cells. Cells were either transfected with Sema 3A siRNA or treated with Sema 3A blocking antibody and used for
migration assay. (D) To study the gain-of-function, wound migration assays were performed using A375 or SK-Mel-28 cells treated with recombinant
exogenous Sema 3A for 18 h. Sema 3A significantly attenuates wound motility of melanoma cells. All the data shown here are the representatives of
triplicate independent experiments.
doi:10.1371/journal.pone.0033633.g002
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3A significantly suppressed invasion in SK-Mel-28 as well as A375
cells (Fig. S1C). Taken together, these data showed that exogenous
Sema 3A inhibits migration and invasiveness of human malignant
melanoma cells. Moreover, we have observed drastic reduction of
invasion of Sema 3A overexpressed melanoma cells (clone 2) as
compared to control (Fig. 3A, panel I). The data were quantified
and represented in the form of bar graph (Fig. 3A, panel II).
Sema 3A abridged in vitro melanoma cell motility
through autocrine and paracrine manner
To determine the effect of Sema 3A on melanoma cell motility,
wound assay was performed as described [28]. The data indicated
that overexpression of Sema 3A significantly attenuated in vitro
melanoma cell motility (Fig. 2B). However, treatment of clone 2 with
anti-Sema 3A or anti-NRP1 blocking antibody drastically induced cell
migration as compared to clone 2-derived cells alone demonstrating
that tumor derived Sema 3A inhibits tumor cell motility through
NRP1 dependent autocrine manner (Fig. 2B). Conditioned media
collected from clone 2 significantly suppressed wound migration of
control B16F10 cells (Fig. 2B) further suggesting that tumor derived
Sema 3A could also suppress tumor cell motility via paracrine
mechanism. On the other hand, silencing endogenous Sema 3A or
blocking Sema 3A activity in B16F1 cells showed enhanced cell
migration (Fig. 2C). These data further demonstrated the significance
of loss-of-function of Sema 3A in melanoma cell migration.
Figure 3. Sema 3A inhibits melanoma cell migration and invasion through autocrine and paracrine mechanisms. (A) Invasion assays
were performed on matrigel coated invasion chamber. Cells (control or clone 2; 1610
5) were plated on upper chamber. After 18 h, invaded cells were
stained with Giemsa and photographed (panel I), counted in 3 high-power fields (C/HPF) under an inverted microscope (Nikon), analyzed statistically
and represented in the form of bar graph (panel II, *P=0.022). (B) Autocrine mechanism of Sema 3A action on melanoma motility and invasiveness
were demonstrated by migration and invasion assay using either B16F10 or clone 2 or B16F1 cells. *p,0.001, $p=0.007, #p=0.003 vs. B16F10. (C)
Boyden chamber migration assay was performed using B16F10 cells to demonstrate the paracrine mechanism of action of Sema 3A. Conditioned
media (CM) collected from clone 2 or B16F1 cells alone or B16F1 transfected with Sema 3A siRNA were used in the lower chamber as a
chemoattractant. In separate experiments, either B16F10 cells treated with Sema 3A (100 ng/ml) or CM from B16F1 treated with Sema 3A antibody
were used in the lower chamber. Migrated cells were counted, analyzed statistically and represented graphically. *p=0.025, **p=0.006 and
$p=0.011 vs. control, #p,0.001, ##p=0.001. (D) Tumor-endothelial interaction was performed in modified Boyden chamber or matrigel coated
invasion chamber. Endothelial cells were placed on upper chamber whereas similar conditioned media (as of Fig. 3C) were used in the lower
chamber. Migrated or invaded cells were stained with Giemsa, photographed, analyzed statistically and represented in the form of graph. *p,0.001
vs. control, **p=0.004, #p=0.01, $p=0.013.
doi:10.1371/journal.pone.0033633.g003
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time melanoma cell motility, wound migration assay was
performed using Time lapse microscopy under the same
experimental conditions as described above. The video demon-
strated that control B16F10 (18 h; Fig. S5) cells exhibit faster
movement and complete closer of wound as compared to clone 2
cells (18 h; Fig. S6). Moreover, incubation of control B16F10 cells
with conditioned media of clone 2 showed significant reduction of
migration as well as exhibit similar motility phenotype like clone 2
cells (18 h; Fig. S7). These data further corroborate that clone 2
derived Sema 3A attenuates motility of control B16F10 cells.
Taken together, the time lapse experimental data demonstrated
that Sema 3A through an autocrine and/or paracrine manner
inhibits melanoma cell motility and may act as potential
suppressor of melanoma progression. To further demonstrate the
role of Sema 3A in melanoma cell migration through autocrine
and paracrine mechanism, Boyden chamber migration assay was
performed where conditioned media (CM) collected from clone 2
or B16F1 cells (with or without Sema 3A siRNA transfection) were
used in the lower chamber as chemoattractant. Moreover, B16F10
cells either treated with Sema 3A (100 ng/ml) or CM collected
from B16F1 treated with Sema 3A antibody were also used in the
migration assay. The data revealed that supplying exogenous
Sema 3A can impede and silencing or inhibiting its activity can
enhance B16F10 migration (Fig. 3C and Fig. S2A). These results
demonstrated that Sema 3A regulates melanoma cell migration
through autocrine (Fig. 3B and Fig. S1B) and paracrine (Fig. 3C
and Fig. S2A) mechanism.
Sema 3A attenuates melanoma cell proliferation
To determine whether overexpression of Sema 3A exerts any
effect on melanoma cell proliferation, MTT assay was performed.
Equal number of control B16F10 and clone 2 cells were grown in
serum free media for 24 h and then incubated with 0.5 mg/ml of
MTT. The proliferation rate of control and clone 2 cells were
analyzed by ELISA reader and plotted graphically (Fig. 4B). The
data showed that overexpression of Sema 3A reduces the cell
viability to 43% of the control. To further confirm this study,
BrdU incorporation assay was performed using Sema 3A treated
SK-Mel-28 cells. Cells were stained with BrdU labeling and
detection kit, visualized under fluorescence microscope, photo-
graphed, analyzed and represented in the form of bar graph. The
data showed significant reduction in BrdU incorporation in Sema
3A treated cells (Fig. S4 A and B).
Enhanced expression of Sema 3A augments p53
phosphorylation
p53, a tumor suppressor protein plays crucial role in regression
of cancer progression [43]. Recent studies have revealed that
phosphorylation of Ser-15 residues of p53 exhibit growth
retardation in melanoma [44]. Tedeschi et al reported that
growth cone retraction by Sema 3A is overcomed by cGMP in
wild type but not in p53 null dorsal root ganglia [45]. In this study,
we have observed that overexpression of Sema 3A inhibits in vitro
tumorigenic phenotype of melanoma cells. Therefore, we sought
to determine whether Sema 3A has any role in suppression of
melanoma progression and the involvement of activated p53 in
this process. Accordingly, control and clone 2 cells were analyzed
by immunofluorescence using anti-phospho p53 (Ser-15) antibody
and analyzed by confocal microscopy (Zeiss). The results indicated
that cells overexpressing Sema 3A enhances p53 phosphorylation
at Ser-15 residue (Fig. 4C, panel I) suggesting the possible
involvement of activated p53 in Sema 3A regulated melanoma
progression. To further validate our findings, SK-Mel-28 cells
were treated with Sema protein (100 ng/ml) for 60 min and
analyzed by immunofluorescence using anti-phospho p53 (Ser-15)
antibody (Fig. 4C, panel II). The results indicated that exogenous
supply of Sema 3A enhances p53 phosphorylation at Ser-15
residue. To further correlate p53 and Sema 3A in clinical samples,
we analyzed the expression profile of Sema 3A and phospho-p53
in normal as well as malignant melanoma clinical specimens.
These data suggested the enhanced expression of Sema 3A and
phospho-p53 in normal skin samples as compared to malignant
melanoma specimens (Fig. S3A and B). These findings further
strengthened the correlation between p53 and Sema 3A in
melanoma progression.
Tumor-derived Sema 3A attenuates melanoma-
endothelial cell interaction through NRP1 dependent
paracrine manner
Our earlier studies have demonstrated that tumor-endothelial
interaction playscrucial role in tumorangiogenesiswhichultimately
promotes tumor progression and angiogenesis [28]. To study the
role of Sema 3A in tumor-endothelial interaction through autocrine
and paracrine mechanisms, co-migration and co-invasion assays
were performed using HUVEC and melanoma cells. Conditioned
media (CM) collected from clone 2 or B16F1 cells (with or without
Sema 3A siRNA transfection) or treated with Sema 3A antibody
were used in the lower chamber. Moreover, HUVECs were also
treated with Sema 3A (100 ng/ml) and used in upper chamber for
co-migration and co-invasion assays. The data depicted that
providing exogenous Sema 3A can reduce and silencing or blocking
endogenous Sema 3A can enhance HUVEC migration/invasion
(Fig. 3D and Fig. S2B), suggesting that Sema 3A regulates
melanoma-endothelial interactions through paracrine mechanism.
Moreover, we have observed the involvement of NRP1 in
tumor-endothelial interaction [28]. NRP1 is identified as one of
the cell surface receptor that interacts with Sema 3A [30,31].
Therefore, to investigate the effect of Sema 3A on tumor-
endothelial interaction, co-migration and co-invasion assays were
performed as described in materials and methods. Our results
revealed that cells overexpressing Sema 3A (clone 2) exhibit
reduced migration and invasion of HUVEC towards tumor cells
(Fig. 4A, panels I and II). However, blocking the endothelial cell-
derived NRP1 has reversed these effects (Fig. 4A, panels I and II).
Taken together our results suggested that overexpression of Sema
3A regulates tumor-endothelial cell interaction through NRP1
dependent paracrine mechanism.
Sema 3A sensitizes melanoma cells in response to
various anti-cancer agents
To examine the effect of various anti-cancer agents in absence
or presence of Sema 3A on melanoma cell death, cell viability
assay was performed. Briefly, both control B16F10 and clone 2
cells were exposed with various anti-cancer agents like curcumin
(0–50 mM) and Dacarbazine (0–400 mM) for 12 h and 24 h
respectively, and the cell viability was determined by MTT assay.
The results have shown that Sema 3A significantly sensitizes
melanoma cells in response to these agents in a dose dependent
manner (Fig. 5A & B).
Curcumin selectively promotes apoptosis in response of
Sema 3A
Earlier we and others have reported that curcumin with higher
doses significantly reduced cell viability and induce apoptotic
phenotype in B16F10 cells [38,46]. In this study, we have observed
that curcumin significantly suppresses the survival of Sema 3A
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cells (Fig. 5B). To further elucidate the effect of curcumin on cell
survival in presence of Sema 3A, both control and clone 2 cells
were incubated with two doses of curcumin, fixed and nuclei were
stained with propidium iodide (PI) and visualized under
fluorescence microscope. The data showed that curcumin even
in lower doses in clone 2 cells is able to induce apoptotic
morphology as compared to parental cells (Fig. 5C).
To further validate the effect of curcumin on cell death, DNA
fragmentation assay was performed. The data showed that clone 2
cells along with low doses of curcumin significantly induce
apoptosis as characterized by marked DNA fragmentation
(Fig. 5D). The curcumin-induced apoptosis was also analyzed by
Western blot using anti-PARP antibody (Fig. 5E). The results also
indicated that curcumin even in low dose is able to induce PARP
cleavage in clone 2 cells.
Sema 3A suppresses in vivo melanoma growth and
angiogenesis in C57BL/6 allograft melanoma model
Our in vitro experimental results prompted us to investigate the
role of Sema 3A on in vivo melanoma progression. Accordingly,
control B16F10 and clone 2 cells were injected subcutaneously to
C57BL/6 mice (n=6/group). In separate experiments, condi-
tioned media (CM) collected from clone 2 cells were injected
intratumorally, twice a week to the tumors generated by injecting
B16F10 cells. After 4 weeks, mice were sacrificed and photo-
graphed, tumors were removed and weighed and represented in
the form of bar graph (Fig. 6A and C). Tumor volumes were
measured, analyzed and represented graphically (Fig. 6D). The
data showed that overexpression of Sema 3A significantly
suppressed in vivo tumor load in C57BL/6 mice. Moreover,
intratumoral injection of CM from clone 2 attenuates tumor
growth of control B16F10 cells in these mice (Fig. 6A and C)
Figure 4. Sema 3A augments p53 phosphorylation and attenuates tumor-endothelial interaction via neuropilin 1 (NRP1) mediated
paracrine mechanism. (A) Tumor-endothelial interaction was performed in modified Boyden chamber or matrigel coated invasion chamber.
Endothelial cells (HUVEC) were placed on upper chamber whereas tumor (control B16F10 or clone 2) cells were used in lower chamber. In separate
experiments, HUVEC were treated with anti-NRP1 blocking antibody and used on the upper chamber. After 18 h, migrated or invaded cells were
stained with Giemsa, photographed (Fig. 4A, panel 1), counted in three high power field (C/HPF) and represented in the form of bar graph (panel II,
*p=0.005 vs. control, **p,0.04 vs. control, #p=0.048 vs. control). The experiments were performed in triplicate. (B) Overexpression of Sema 3A
inhibits cell viability of B16F10 cells. Equal number of control B16F10 or clone 2 cells (1610
4) were grown in 96 well tissue culture plates and cell
viability was performed by MTT assay. The data are represented in the form of bar graph (*p=0.011) and the mean value of triplicate experiments is
indicated. (C) Sema 3A augments Ser-15 phosphorylation of p53. The phosphorylation at Ser-15 of p53 was analyzed by immunofluorescence using
specific antibody followed by Cy3 (red) labeled secondary antibody. Photographs were taken under confocal microscope at 606 magnification
(Fig. 4C, panel I). The typical photographs have shown here represents three independent experiments exhibiting similar results. Similarly, SK-Mel-28
cells were treated with Sema 3A (100 ng/ml) and the level of phospho-p53 at Ser-15 was analyzed by confocal microscopy (Fig. 4C, panel II).
doi:10.1371/journal.pone.0033633.g004
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regression of melanoma growth.
The tumor sections were analyzed histopathologically using
H&E staining and the photographs were taken at 106 and 606
magnifications (Fig. 6B). The data showed that tumors generated
by control B16F10 cells exhibit higher infiltration, poorly
differentiated structure, enhanced nuclear polymorphism and
increased number of tumor giant cells as compared to the tumors
generated by clone 2 or CM of clone 2 (Fig. 6B). The data
demonstrated that Sema 3A significantly attenuates in vivo
melanoma growth. The tumor sections were also analyzed
immunohistochemically using anti-vWF antibody. The results
showed that there is a significant enhancement of tumor
angiogenesis in tumor sections generated by control B16F10 cells
as compared to clone 2 (Fig. 6B), indicating that overexpression of
Sema 3A attenuates melanoma growth and angiogenesis in
allograft tumor models via an autocrine or paracrine mechanism.
To further examine the potential role of Sema 3A in tissue
specific metastasis in melanoma models, the allograft melanoma
tumors as shown in Fig. 6A, were ventrally dissected and
metastatic lesions such as liver, intestine and kidney were
separated and analyzed by histopathologically (606) (Fig. 7A,
panels II–IV). The data indicated that tumors generated by
control cells augment metastasis in liver, intestine and kidney
whereas Sema 3A clone 2 or CM of clone 2 dramatically
suppressed these metastasis (Fig. 7A, panels I–IV) demonstrating
that Sema 3A inhibits melanoma growth, angiogenesis and
metastasis in subcutaneous C57BL/6 mice models.
Figure 5. Sema 3A overexpressed clone exhibits increased drug sensitivity in B16F10 cells. (A) Control or clone 2 cells were treated with
melanoma specific drug, Dacarbazine (DTIC) (0–400 mM) for 24 h and cells survival was analyzed by MTT assay. #p=0.393, *p,0.001, **p=0.002 vs.
respective treatment group within B16F10 and clone 2 cells. (B) Similarly, both cells were treated with curcumin (0–50 mM) for 12 h and cell viability
was checked by MTT assay. The data are represented in the form of bar graph and the mean value of triplicate experiments is indicated. #p=0.074,
*p,0.001, **p=0.044 vs. respective treatment group within B16F10 and clone 2 cells. (C) Both cells were treated with indicated concentrations of
curcumin, fixed and stained with PI (red) and photographed under fluorescence microscope at 606 magnifications. The apoptotic nuclei are
indicated by arrows. (D) Cells were treated with two doses of curcumin for 12 h. Fragmentation of genomic DNA was extracted and resolved on 2%
agarose gel. Apoptotic DNA fragmentation was visualized by ethidium bromide staining. (E) Curcumin induced apoptosis in control and clone 2 cells
were also analyzed by Western blot using anti-PARP antibody. Cells were treated with 0–50 mM curcumin for 12 h and then analyzed by Western blot.
a-Tubulin was used as loading control. The experiments showed here are representative of triplicate independent experiments with similar results.
doi:10.1371/journal.pone.0033633.g005
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To determine whether Sema 3A inhibits melanoma metastasis,
we implanted melanoma (control or clone 2) cells into the arterial
circulation via intracardiac injection. After 18 days, mice were
sacrificed, dissected and photographed (Fig. 7B, panel I). Mice
with uninjected cells were used as control. The data suggested the
significant melanoma metastasis in liver and intestine of control
B16F10 but not in clone 2 injected mice (Fig. 7B, panels II & III).
Moreover, we have detected several metastatic foci in the tissue
sections of liver and intestine of control B16F10 injected mice by
histopathology using H&E staining. The lungs of these mice were
photographed and analyzed histopathologically. Significant lung
metastasis was observed in control B16F10 but not in clone 2 cells
injected mice (Fig. 7B, panels IV & V). Overall, the data clearly
provided evidence that overexpression of Sema 3A significantly
attenuates melanoma metastasis to lung, liver and intestine in
murine melanoma model.
Discussion
In this study, using various in vitro as well as in vivo models, we
have demonstrated for the first time that Sema 3A could act as a
potential tumor suppressor in melanoma model. The data also
revealed that Sema 3A could be a rational and effective
therapeutic molecule for treatment of melanoma. Our conclusion
is supported by several lines of evidences: (i) expression profile of
Sema 3A is negatively correlated with melanoma progression in
human clinical specimens; (ii) overexpression of Sema 3A
attenuates in vitro cell motility, invasiveness and proliferation in
highly metastasic melanoma cells; (iii) tumor derived Sema 3A
abrogated tumor-endothelial interaction via NRP1 mediated
paracrine mechanism; (iv) Sema 3A promotes drug sensitivity of
melanoma cells; (v) Sema 3A alone is not able to induce apoptosis
however it enhances the apoptotic potential of curcumin and
DTIC in B16F10 cells; (vi) overexpression of Sema 3A significantly
Figure 6. Overexpression of Sema 3A abrogates in vivo melanoma growth and angiogenesis in subcutaneous allograft tumor model
in C57BL/6 mice. Control B16F10 and clone 2 cells (1610
6/mice) were injected subcutaneously into the dorsal flank region of male mice (6–8 weeks
old; n=6). In separate experiments, serum free conditioned media (CM) collected from clone 2 cells were injected intratumorally twice a week to the
tumors generated by B16F10 cells upto termination of the experiments (n=6). Mice were sacrificed after 4 weeks. (A) Typical photographs of
subcutaneous melanoma in C57BL/6 mice and excised tumors of respective mice were shown. (B) Mice allograft tumors were analyzed by
histopathology and immunohistochemistry using anti-vWF antibody. vWF was stained with Cy2 (green) whereas nuclei were countered stained with
PI (red). (C) Weight of the excised tumors were measured, analyzed and represented in the form of bar graph (*p=0.006,
#p=0.002). (D) Tumor
volumes of the allograft melanoma tumors were measured weekly, analyzed and plotted graphically. Six mice were used in each set of experiments.
doi:10.1371/journal.pone.0033633.g006
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subcutaneous melanoma model, (vii) Sema 3A suppresses
metastasis in melanoma models developed upon intracardiac
injection and finally (viii) Sema 3A regulates melanoma cell
migration and invasion through autocrine and paracrine mecha-
nisms. Altogether, our experimental evidences suggested that
Sema 3A acts as a potential tumor suppressor in melanoma model.
Angiogenesis has been demonstrated as one of the major event
during malignant progression of cancer [47]. Recent advancement
of cancer therapeutics indicated that targeting tumor angiogenesis
could be one of the rational and promising approaches for the
treatment of cancer. Earlier studies have shown that among
various members of semaphorin family, Sema 3A could act as a
potential suppressor of angiogenesis [13–16,33], however the
molecular mechanism underlying this process is not clearly
understood and has been a field of intense investigation. In this
study, using various in vitro as well as in vivo models, we have
demonstrated that Sema 3A could suppress melanoma progres-
sion. Our clinical data for the first time revealed that melanoma
growth negatively correlated with expression profile of Sema 3A.
Earlier we have reported the crucial role of NRP1 in regulation of
tumor endothelial interaction which ultimately regulates tumor
angiogenesis [28]. In this study, we have shown that B16F10
overexpressed Sema 3A disrupts tumor-endothelial interaction
through NRP1 mediated process. Furthermore, we have detected
significant reduction of tumor angiogenesis in Sema 3A overex-
pressed clone when injected subcutaneously into C57BL/6 mice.
In summary, our experimental observations have clearly indicated
that Sema 3A may act as a potential suppressor of melanoma
progression by attenuating angiogenesis.
Metastasis or the distant migration of cancer cells from the site
of origin is the major cause of death by cancer [48]. Metastasis is a
multistep process involving motility and invasion of cancer cells,
intravasation, transit through vascular and/or lymphatic system,
extravasation and growth of secondary tumor at new site [49].
Therefore, prevention of migration and metastasis of cancer cells is
the center of attention for researchers and oncologists [48]. In this
study, we have shown that Sema 3A attenuates in vitro melanoma
Figure 7. Sema 3A overexpression attenuates melanoma metastasis. (A) The mice described in Fig. 6A, were dissected ventrally and
photographed. Growth of melanoma tumors were indicated by arrows (Fig. 7A, panel I). Internal organs (liver, intestine and kidney) were analyzed
histopathologically and the micrographs were shown at 606magnification (Fig. 7A, panels II–IV). Melanoma positive cells in metastatic lesions were
marked by red arrows, whereas surrounding stromal regions were indicated by black arrows. Six mice were used in each group. Un-injected mice are
used as control. (B) Sema 3A attenuates melanoma metastasis in mice. Control or clone 2 cells were injected intracardiaclly and mice were sacrificed,
dissected ventrally and photographed (Fig. 7B, panel I). Metastasized organs were indicated by arrows. Liver and intestine of the mice were analyzed
histopathologically by H&E staining (Fig. 7B, panels II & III). Micrographs were taken at 106magnification. Arrows showed the melanoma foci. Fig. 7B,
panel IV shows the excised lung of respective mice. Lung sections were also analyzed histopathologically and photographs were taken at 106
magnification (Fig. 7B, panel V). Melanoma metastatic foci in lung sections are indicated by arrows. Six mice were used in each set of experiment. Un-
injected mice were used as control.
doi:10.1371/journal.pone.0033633.g007
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copy data have clearly indicated that Sema 3A significantly
reduced the migration of melanoma cells. Earlier it has been
reported that p53 inhibits lung metastasis in B16F10 cells [50]. We
have also observed that overexpression of Sema 3A augmented the
activation of p53 in various melanoma models. Moreover, we have
correlated the Sema 3A and p53 phosphorylation at Ser-15 in
melanoma clinical specimens. Therefore, the inhibitory effect of
Sema 3A on melanoma cells may be p53 dependent, although
extensive study is required to understand such mechanism.
Furthermore, our allograft data have shown that Sema 3A
overexpression drastically reduced in vivo melanoma growth
and metastasis. Moreover, attenuation of tumor growth by
intratumoral injection of CM of clone 2 indicates that tumor
secreted Sema 3A also suppressed tumor growth via paracrine
mechanism.
In recent time, treatment of cancer patients with anticancer
agents/drugs (cancer chemotherapy) has shown greater promises;
although there is some limitation of such therapy. Drug resistance
of cancer cells has been known as the major burden for cancer
chemotherapy and exhibit frequent clinical problem in patients.
Therefore, development of novel therapeutic approach to
overcome the drug resistance and increase the drug sensitivity of
cancer cells remains a major challenge for the successful
chemotherapy of cancer. In this study, we have noted that
overexpression of Sema 3A in presence of various pharmacological
anti-cancer agents (curcumin and DTIC) decreased cell survival as
compared to control B16F10 cells. Moreover, we have observed
that curcumin, even at comparatively lower doses significantly
promotes apoptosis in Sema 3A overexpressed cells. Our live cell
imaging data also suggested that fraction of control cells were
escaped from apoptosis when they were incubated with curcumin
(data not shown). Taken together, our experimental observations
indicated that Sema 3A has no significant effect on melanoma cell
survival but it increases the drug sensitivity of B16F10 cells.
This study highlights that Sema 3A attenuates the metastatic
signature and angiogenic switch in melanoma model which
ultimately suppresses melanoma progression. The data revealed
that Sema 3A increases drug sensitivity of melanoma cells. The
results demonstrate that chemotherapy of cancer by anti-cancer
agents along with combination of Sema 3A could be a rational and
promising approach for the treatment of cancer. The study
suggests that Sema 3A regulated pathway may act as potentially
important therapeutic target for the management of malignant
melanoma.
Supporting Information
Figure S1 Expression profile of Sema 3A in human
melanoma cells and its role in melanoma migration and
invasion. (A) Total RNA was isolated from human melanoma
cells (A375 and SK-Mel-28) and Q-PCR analysis of Sema 3A
expression was performed. Bar graph represents the normalized
Sema 3A mRNA with GAPDH. *p,0.001. (B) Representative
photographs of migrated/invaded melanoma cells were shown in
S1B and the bar graphs were shown in Fig. 3B. (C) Invasion assays
were performed with A375 and SK-Mel-28 cells either in absence
or presence of Sema 3A recombinant protein. Invaded cell were
counted and represented in the form of graph (Fig. S1C, panels I
& II).
(TIF)
Figure S2 Sema 3A inhibits melanoma migration and
melanoma-endothelial cell interaction through para-
crine mechanism. (A) Representative photographs of migrated
B16F10 cells showing Sema 3A abrogates melanoma migration
through paracrine manner as described in Fig. 3C. (B)
Photographs of migrated and invaded HUVEC showing Sema
3A attenuates melanoma-endothelial interaction as shown in
Fig. 3D.
(TIF)
Figure S3 Immunohistochemical analyses of human
normal skin biopsy and malignant melanoma tissues
by using anti-phospho-p53 antibody. Two normal skin
biopsy (A) and three malignant melanoma (B) specimens were
analyzed immunohistochemically for visualizing the expression of
Sema 3A (Fig. S3A, panels a, b & Fig. S3B panels a–c) and
phospho-p53 of Ser-15 (Fig. S3A, panels e, f & Fig. S3B, panels g–
i). Nuclei were stained with DAPI (Cy2 in green, Cy3 in red and
DAPI in blue).
(TIF)
Figure S4 Sema 3A controls melanoma cell prolifera-
tion. SK-Mel-28 cells were plated on coverslip in 24 well plates.
The cells were treated with 100 ng/ml Sema 3A for 24 h followed
by incubation with complete media supplemented with BrdU for
another 24 h. Cells were stained with BrdU labeling and detection
kit, visualized under fluorescence microscope, counted and
photographed (A)a t1 0 6 magnification and represented in the
form of bar graph (B). *p=0.0022. Nuclei were stained with
DAPI.
(TIF)
Figure S5 Time lapse videograph of wound migration of
B16F10 cells. Confluent monolayer of B16F10 cells was
wounded and the migration of the cell towards the wound was
monitored and photographed under Nikon time laps microscope
in an interval of 10 min up to 18 h and represented in the form of
video using Image Pro-Plus software after compiling the images
into a movie.
(MP4)
Figure S6 Time lapse videograph of wound migration of
Sema 3A overexpressed B16F10 cells (clone 2). Confluent
monolayer of clone 2 cells was wounded and the migration of the
cell towards the wound was monitored and photographed under
Nikon time laps microscope in an interval of 10 min up to 18 h
and represented in the form of video using Image Pro-Plus
software after compiling the images into a movie.
(MP4)
Figure S7 Time lapse videograph of wound migration of
B16F10 cells treated with conditioned media (CM) of
Sema 3A overexpressed B16F10 cells (clone 2). Confluent
monolayer of control cells was wounded, treated with CM
collected from clone 2 cells and the migration of cells toward
the wound was monitored and photographed under Nikon time
laps microscope in an interval of 10 min up to 18 h and
represented in the form of video using Image Pro-Plus software
after compiling the images into a movie.
(MP4)
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